IDEXX Laboratories (NASDAQ:IDXX) Director Lawrence Kingsley Sells 2,203 Shares

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Lawrence Kingsley sold 2,203 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the transaction, the director owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

IDEXX Laboratories Trading Down 1.0%

Shares of IDXX stock opened at $515.15 on Thursday. IDEXX Laboratories, Inc. has a fifty-two week low of $511.16 and a fifty-two week high of $769.98. The stock’s fifty day moving average price is $557.68 and its two-hundred day moving average price is $567.79. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The company has a market cap of $40.58 billion, a PE ratio of 36.23, a P/E/G ratio of 2.78 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter in the previous year, the firm earned $3.50 EPS. IDEXX Laboratories’s revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Citigroup upped their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Barclays cut their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, UBS Group upped their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $747.00.

Hedge Funds Weigh In On IDEXX Laboratories

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. SHP Wealth Management bought a new stake in shares of IDEXX Laboratories in the fourth quarter worth $26,000. Virtus Advisers LLC bought a new stake in IDEXX Laboratories in the third quarter valued at approximately $26,000. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories during the 2nd quarter worth approximately $25,000. Elevation Wealth Partners LLC lifted its position in shares of IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after purchasing an additional 32 shares during the period. Finally, Wormser Freres Gestion raised its stake in IDEXX Laboratories by 671.4% during the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after buying an additional 47 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.